Michael Ehlers is a prominent figure in the biotechnology industry, with a strong background in research and leadership roles. Michael is currently leading Ascidian Therapeutics, a company focusing on designer synthetic RNA therapeutics and RNA exon editing for various diseases. Additionally, Michael holds key positions in other innovative biotechnology companies such as Replicate Bioscience, Aulos Bioscience, and Intergalactic Therapeutics. With a MD, PhD in Medicine and Neuroscience from The Johns Hopkins University School of Medicine, Michael Ehlers has a solid foundation for their impactful work in the field.